VIVUS (STU:VIU1) Total Liabilities : €262.33 Mil (As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Total Liabilities?

VIVUS's Total Liabilities for the quarter that ended in Mar. 2020 was €262.33 Mil.

VIVUS's quarterly Total Liabilities declined from Sep. 2019 (€262.75 Mil) to Dec. 2019 (€258.78 Mil) but then increased from Dec. 2019 (€258.78 Mil) to Mar. 2020 (€262.33 Mil).

VIVUS's annual Total Liabilities increased from Dec. 2017 (€231.79 Mil) to Dec. 2018 (€300.77 Mil) but then declined from Dec. 2018 (€300.77 Mil) to Dec. 2019 (€258.78 Mil).

VIVUS Total Liabilities Historical Data

The historical data trend for VIVUS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Total Liabilities Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Liabilities

Get a 7-Day Free Trial

260.98

272.64

231.79

300.77

258.78

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Total Liabilities	Get a 7-Day Free Trial															298.62	298.35	262.75	258.78	262.33

VIVUS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

VIVUS's Total Liabilities for the fiscal year that ended in Dec. 2019 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	202.631	+	(53.391	+	-2.2204460492503E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.757	+	0)
	=	258.78

Total Liabilities	=	Total Assets (A: Dec. 2019 )	-	Total Equity (A: Dec. 2019 )
	=	196.477	-	-62.302
	=	258.78

VIVUS's Total Liabilities for the quarter that ended in Mar. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	206.146	+	(53.675	+	1.4654943925052E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.506	+	0)
	=	262.33

Total Liabilities	=	Total Assets (Q: Mar. 2020 )	-	Total Equity (Q: Mar. 2020 )
	=	195.397	-	-66.93
	=	262.33

VIVUS Total Liabilities Related Terms

Thank you for viewing the detailed overview of VIVUS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines